Gerry Hanna, Marie Curie Chair of Clinical Oncology at Trinity College Dublin, shared a post on X about a paper by Hongfu Sun et al. published in the Journal of Clinical Oncology:

“Interesting paper just out in Journal of Clinical Oncology.

Chinese study in patients with EGFR positive oligo-organ metastatic NSCLC. TKI plus RT group received 60Gy to primary and positive LNs. RT to metastases determined by clinicians.

Median OS was 26.2 months and 34.4 months (RT).”

“Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial”

Authors: Hongfu Sun et al.

Gerry Hanna: Chinese study in patients with EGFR positive oligo-organ metastatic NSCLC